A proposed Centers for Medicare & Medicaid Services (CMS; Baltimore) national coverage decision involving Cambridge Heart's (Bedford, Massachusetts) Microvolt T-Wave Alternans (MTWA) cardiac diagnostic testing may have far-reaching impact across a substantial swath of the cardiovascular device sector.